UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 97 filers reported holding UNIQURE NV in Q2 2018. The put-call ratio across all filers is 0.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $511,000 | +96.5% | 7,128 | +8.3% | 0.00% | +100.0% |
| Q3 2019 | $260,000 | -59.9% | 6,583 | -20.6% | 0.00% | -60.0% |
| Q2 2019 | $648,000 | +21.6% | 8,296 | -7.2% | 0.01% | +25.0% |
| Q1 2019 | $533,000 | +85.1% | 8,939 | -10.3% | 0.00% | +33.3% |
| Q4 2018 | $288,000 | -16.3% | 9,966 | +5.3% | 0.00% | 0.0% |
| Q3 2018 | $344,000 | +21.6% | 9,464 | +26.5% | 0.00% | -25.0% |
| Q2 2018 | $283,000 | +55.5% | 7,480 | -3.2% | 0.00% | +33.3% |
| Q1 2018 | $182,000 | +22.1% | 7,725 | +1.8% | 0.00% | +50.0% |
| Q4 2017 | $149,000 | +106.9% | 7,589 | +0.9% | 0.00% | +100.0% |
| Q3 2017 | $72,000 | +75.6% | 7,520 | +13.9% | 0.00% | 0.0% |
| Q2 2017 | $41,000 | +70.8% | 6,600 | +60.0% | 0.00% | – |
| Q1 2017 | $24,000 | +84.6% | 4,126 | +74.2% | 0.00% | – |
| Q4 2016 | $13,000 | -35.0% | 2,368 | -9.5% | 0.00% | – |
| Q3 2016 | $20,000 | +11.1% | 2,616 | +3.0% | 0.00% | – |
| Q2 2016 | $18,000 | – | 2,541 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |